Bayer

Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

FY 2005 Results - Publication Schedule

Ladies and Gentlemen,

For the release of our Full Year 2005 results we set up the following schedule:

Monday, March 6, 2006

7:30 a.m. CET: **FY 2005 Information Package**

via email and fax and available on the internet at:
www.investor.bayer.com / www.investor.bayer.de

To get a quick overview the structure of the information package will be as follows:
1) Q4 2005 Analyst and Investor Briefing
2) Press release on FY 2005 results
3) Financial Statements 2005

Annual Report 2005
available on the internet at:
www.investor.bayer.com / www.investor.bayer.de

12:00 noon CET: **Presentation charts**
available for download on the internet at:
www.live.bayer.com / www.live.bayer.de

4:30 p.m. CET: **FY 2005 Investor Conference Call**
with Werner Wenning (CEO of Bayer AG), Klaus Kühn (CFO of Bayer AG), Arthur J. Higgins (CEO of Bayer HealthCare), Friedrich Berschauer (CEO of Bayer CropScience) and Hagen Noerenberg (CEO of Bayer MaterialScience)

Dial-in Numbers
International: +44-207-154-2666
UK: 0207-154-2666
US: +1-866-864-9344
Germany: 06103-485-3000

If you are unable to participate in the conference, a recording will be available for access by touch tone telephone until March 9.
Replay Dial-in Numbers
International: +44-208-515-2499, Passcode: 146555#
UK: 0208-515-2499, Passcode: 446555#
US: +1-303-590-3000, Passcode: 11054497#
Germany: 069-5899-90568, Passcode: 133757#

Live audio broadcast (English only) on the internet at:
www.live.bayer.com / www.live.bayer.de

An on-demand version of the conference call webcast will be available on the same day at 8:00 p.m. CET.

Best regards,
Bayer Investor Relations

Bayer



Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

Investor News

Treatment of central venous catheter occlusion:

Bayer HealthCare and Nuvelo begin second pivotal phase III trial of lead product candidate, alfimeprase

Leverkusen / February 27, 2006 – Bayer HealthCare (BHC) and Nuvelo Inc. (Nasdaq: NUVO) today announced that they have begun patient enrollment in a second pivotal phase III clinical trial of lead product candidate, alfimeprase, for the treatment of central venous catheter occlusion (CO). Alfimeprase is a novel thrombolytic or blood clot dissolver.

The phase III trial, known as SONOMA-3 (Speedy Opening of Non-functional and Occluded catheters with Mini-dose Alfimeprase-3), is the second of two overlapping, multi-national trials in the phase III alfimeprase program for CO. This open-label, single-arm trial will evaluate the safety and efficacy of 3 mg of alfimeprase in 800 patients with occluded central venous catheters.

In January 2006 Bayer HealthCare AG (BHC) and Nuvelo Inc. announced that they entered into a collaboration agreement for the global development and commercialization of alfimeprase. Under the terms of the agreement, Bayer will commercialize alfimeprase in all territories outside the United States.

"We believe that alfimeprase has the potential to quickly dissolve clots and rapidly restore the ability to infuse critical therapy such as chemotherapy or antibiotics through once occluded catheters," said Steven R. Deitcher, M.D., vice president of medical sciences for Nuvelo and former principal investigator of the phase II trial. "We look forward to completing the first trial in this program, SONOMA-2, later this year and expect the phase III trial results to confirm the ability of alfimeprase to restore function to occluded catheters in 15 minutes or less, as demonstrated in our phase II trial."

Previously announced results from a phase II multi-center, randomized, double-blind study in 55 patients with occluded central venous catheters demonstrated that alfimeprase restored flow to 40 percent and 50 percent of occluded catheters 5 and 15 minutes after the first dose, respectively. By comparison, Cathflo®Activase® (alteplase) did not restore flow at either time point. Alfimeprase also restored flow to 60 percent of occluded catheters at 120 minutes after the first dose and to 80 percent of occluded catheters at 120 minutes after the second dose compared with 46 percent at 120 minutes after the first dose and 62 percent at 120 minutes after the second dose with Cathflo®Activase®.

About Catheter Occlusion

Delivery of chemotherapy, nutritional support, antibiotics and blood products, as well as the frequent withdrawal of blood samples for laboratory testing, are often facilitated via central venous catheters. Approximately 5 million catheters are placed in patients in the United States each year, with as many as 25 percent becoming occluded. When a catheter becomes occluded, the goal is to restore flow in a prompt and cost-effective manner with minimal risk to the patient. As these catheters are primarily inserted in patients receiving life-saving medications such as chemotherapy, it is critical to restore flow through the catheter as soon as possible. In the case of thrombotic occlusions, treatment with thrombolytic drugs represents a less-invasive and more cost-effective alternative to replacement. Currently, Cathflo®Activase® is approved in the United States for restoring function to central venous catheters.

Additional Clinical Trials

The first study in the ongoing phase III clinical program in CO, SONOMA-2, began in September 2005 and is expected to complete enrollment in the second half of this year. This randomized, double-blind study is comparing the efficacy of 3 mg of alfimeprase with placebo in 300 patients with occluded central venous catheters. Two-thirds of the participants are receiving alfimeprase and the remainder are receiving placebo. The primary endpoint is restoration of catheter function within 15 minutes.

Alfimeprase is also being studied in an ongoing phase III program known as the NAPA (Novel Arterial Perfusion with alfimeprase) program, for the treatment of acute peripheral arterial occlusion (PAO), or "leg attack." The program consists of two overlapping, randomized, double-blind, multi-national trials comparing 0.3 mg/kg of alfimeprase with placebo in a total of 600 patients. The primary endpoint in both trials

is avoidance of open vascular surgery within 30 days of treatment. A variety of secondary endpoints are also being evaluated, including safety endpoints such as the incidence of bleeding, and pharmacoeconomic endpoints such as length of hospital and intensive care unit (ICU) stay. The first trial in this program, NAPA-2, is expected to complete enrollment in the second half of this year. The second trial, NAPA-3, is expected to begin in early 2006 and is being conducted under a special protocol assessment from the FDA.

In January 2006, Nuvelo received fast track designation from the U.S. Food and Drug Administration (FDA) for the NAPA program. Fast track designation is reserved for new drugs that demonstrate the potential to address an unmet medical need and are intended for the treatment of a serious or life-threatening condition.

In addition, Nuvelo recently announced plans to initiate a phase II trial of alfimeprase for the treatment of ischemic stroke in the second half of 2006, and a phase II trial of alfimeprase for the treatment of deep venous thrombosis in 2007.

About Bayer HealthCare AG
Bayer HealthCare AG, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the health care and medical products industry. In 2004, the Bayer HealthCare subgroup generated sales amounting to some 8.5 billion Euro.

The company combines the global activities of the divisions Animal Health, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals. Since January 1, 2006 the new Pharmaceutical Division consists of the former Biological Products and Pharmaceutical Division and now comprises three business units:
Hematology/Cardiology; Oncology and Primary Care.
Bayer HealthCare employed 35,300 people worldwide in 2004.

Bayer HealthCare's aim is to discover and manufacture innovative products that will improve human and animal health worldwide. The products enhance well-being and quality of life by diagnosing, preventing and treating disease.

Leverkusen, February 27, 2006

Bayer AG. Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)
Dr. Juergen Beunink (+49-214-30-65742)
Peter Dahlhoff (+49-214-30-33022)
Ilia Kürten (+49-214-30-35426)
Ute Menke (+49-214-30-33021)
Judith Nestmann (+49-214-30-66836)

Forward-looking statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Bayer

Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

Investor News

Bayer responds to report in "Capital" magazine

Leverkusen / March 1, 2006 – Bayer has issued the following response to the advance article in "Capital" magazine concerning the Bayer Group's plans.

Bayer regrets that working documents of corporate management have been made public. These are planning documents that are used solely for internal working purposes. Internal planning data of this nature must never be viewed as concrete expectations, estimates or forecasts of the company. Generally speaking, planning data are based on various assumptions covering, for example, future currency trends, raw material prices and economic developments, which significantly influence actual performance. As is our normal practice, suitable forecast data are published officially by the company only when they become sufficiently reliable.

The two figures that have now been made public and which refer to fiscal 2005 require slight correction. Group net income in 2005 is expected to be EUR 1.6 billion and not – as incorrectly stated by "Capital" – EUR 1.8 billion. This figure is in line with market expectations. Bayer's Supervisory Board will decide at its meeting tomorrow on the dividend payment to be proposed. The Board of Management will recommend an increase in the dividend of more than 70 percent to EUR 0.95 and not EUR 0.90, as reported by "Capital."

Bayer will be reporting in detail on its performance in fiscal 2005 and its expectations for 2006 at its Spring Financial News Conference being held on Monday, March 6, in Leverkusen. The dividend proposal for 2005 by the Management Board and Supervisory Board will be published following the Supervisory Board meeting on Thursday, March 2.

Leverkusen, March 1, 2006

Bayer AG, Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)
Dr. Juergen Beunink (+49-214-30-65742)
Peter Dahlhoff (+49-214-30-33022)
Ilia Kürten (+49-214-30-35426)
Ute Menke (+49-214-30-33021)
Judith Nestmann (+49-214-30-66836)

Forward-looking statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Bayer



Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

Investor News

Bayer proposes increasing dividend to EUR 0.95

Thomas de Win elected Vice Chairman of the Supervisory Board

Leverkusen / March 2, 2006 – Bayer AG's Supervisory Board today accepted the proposal of the Board of Management to recommend to the Annual Stockholders' Meeting on April 28, 2006, a dividend for fiscal 2005 of EUR 0.95 per share. With some 730 million shares. this would represent a payout of EUR 694 million, an increase of 73 percent. For fiscal 2004, a dividend of EUR 0.55 per share was paid.

"Fiscal 2005 was a very good year for Bayer and we would like our stockholders to participate appropriately in our success," says Werner Wenning, Chairman of the Board of Management. The Bayer Group's financial statements will be presented and discussed at the Spring Financial News Conference on March 6, 2006.

The Supervisory Board also elected Thomas de Win as its Vice Chairman. He takes over from Erhard Gipperich, who retired at the end of January 2006. "We would like to thank Mr. Gipperich for his contribution and wish Mr. de Win all the best in his new post," said Supervisory Board Chairman Dr. Manfred Schneider.

Before the Supervisory Board meeting de Win (47) had been appointed Chairman of the Bayer Central Works Council. He has been a member of the Supervisory Board since April 2002.

Leverkusen, March 2, 2006

Bayer AG, Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)
Dr. Juergen Beunink (+49-214-30-65742)
Peter Dahlhoff (+49-214-30-33022)
Ilia Kürten (+49-214-30-35426)
Ute Menke (+49-214-30-33021)
Judith Nestmann (+49-214-30-66836)

Forward-looking statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.